Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers

Lectura recomendada por el Lectura recomendada por el Dr. Mauricio Luongo. 

Conferencia 2024: “Presente de los tratamientos con Inmunoradioterapia.»

• Autores: David A Palma, Robert Olson, Stephen Harrow, Stewart Gaede et al.
• Fuente: Lancet 2019; 393: 2051–58.

Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial

Descargar